Clinical trial
A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT03504397 is registered in ClinicalTrials.gov with Astellas Pharma Global Development, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- June 21, 2018
- Completion date
- September 30, 2026
- Enrollment
- 565 (actual)
- Sites
- 220
Conditions
As the registry lists them; a condition with its own page is linked.
locally advanced unresectable gastric adenocarcinoma or cancer, locally advanced unresectable gastroesophageal junction (gej) adenocarcinoma or cancer, metastatic gastric adenocarcinoma or cancer, metastatic gastroesophageal junction (gej) adenocarcinoma